Literature DB >> 31837942

A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer.

G Liberale1, C-F Pop2, L Polastro3, J Kerger3, M Moreau4, M Chintinne5, D Larsimont5, J M Nogaret2, I Veys2.   

Abstract

INTRODUCTION: Cytoreductive surgery of locally advanced ovarian cancer has evolved in the last few years from surgery to remove macroscopic residual disease (<1cm; R2b) to macroscopic complete cytoreductive surgery with no gross residual disease (R1). The aim of this study was to evaluate the impact of the adoption of a maximalist surgical approach on postoperative complications, disease recurrence and survival.
MATERIALS AND METHODS: This was a retrospective study using prospectively collected data on patients who received either conservative approach (CA) or radical approach (RA) surgical treatment for primary ovarian cancer stage IIIc/IVa/IVb between June 2006 and June 2013.
RESULTS: Data for 114 patients were included, 33 patients in the CA group and 68 patients in the RA group were consequently analysed. In the RA group, operative time was longer, in relation to more complex surgical procedures; with more blood losses and a higher rate of compete macroscopic resection. Totally, 77% of the patients had postoperative complications, with more grade I/II complications in the RA group but the same rates of grade III/IV complications in the both groups (P=0.14). For all patient study population, the overall and disease-free survivals were improved in case of no macroscopic residual disease. Overall survival was improved in the RA group (P=0.05), with no difference in terms of disease-free survival (P=0.29)
CONCLUSION: A radical approach in advanced ovarian cancer allows a higher rate of complete cytoreductive surgery impacting overall survival. However, a non-significant trend for increased mild complications (grade I/II) rate is observed in this group.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cytoreductive surgery; Macroscopic residual disease; Ovarian cancer; Peritoneal carcinomatosis

Mesh:

Year:  2019        PMID: 31837942     DOI: 10.1016/j.jviscsurg.2019.12.002

Source DB:  PubMed          Journal:  J Visc Surg        ISSN: 1878-7886            Impact factor:   2.043


  2 in total

Review 1.  Narrative review of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer: a critical reappraisal of the current evidence.

Authors:  John Spiliotis; Anastasia Prodromidou
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 2.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.